TLR9 and non-small cell lung carcinoma: Ongoing clinical studies are examining the use of TLR9 agonists in combination with local radiation and immunotherapy (NCT03410901) for the treatment of refractory lymphomas or conventional chemotherapy (paclitaxel and carboplatin) for the treatment of NSCLC [64].